Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

company's website until the next earnings call.

About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to commercial launch preparations, anticipated timing of commercial launch and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9,
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
(Date:1/14/2014)... MO (PRWEB) January 14, 2014 Holloway ... comprehensive database of material test reports (MTRs) for all ... fabricates. Documenting test results is particularly important for equipment ... regulations. The MTR Library features search functionality that allows ...
Breaking Biology Technology:Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... and NEWTON, Mass., April 17 ,InforMedix Holdings, ... and Med-eXpert(TM) Systems to improve,medication adherence and ... prescription medication adherence solutions, announced an,agreement to ... to a broad spectrum of,Federal and State ...
... Professor,s fight against pancreatic cancer and underscores, his call-to-action for additional research ... ... of Lustgarten Foundation,s limited online book offer,as seen on ABC Primetime with Diane ... Last Lecture" were ...
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
Cached Biology Technology:InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 2InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 3InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 4InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 5The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch 2Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2
(Date:4/18/2014)... used techniques like X-ray crystallography and nuclear magnetic resonance ... structure of molecules, but such efforts have long been ... of a specific molecule and often in ordered and ... but impossible to peer into the structure of most ... soon be a thing of the past. , ...
(Date:4/18/2014)... as they,re planted may be good news for a garden. ... wild, a plant whose seeds sprouted at the first ,warm ... an insurance policy against late frosts or unexpected dry spells, ... Plants whose seeds put off sprouting until conditions are ... team of researchers working at the National Evolutionary Synthesis Center ...
(Date:4/17/2014)... clinical trials to treat tuberculosis could be the basis ... various bacteria, fungal infections and parasites, yet evade resistance, ... and collaborators. , Led by U. of I. chemistry ... the drug SQ109 attacks the tuberculosis bacterium, how the ... yeast to malaria and how targeting multiple pathways ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2
... the cells responsible for immune surveillance in the brain, ... tissue damage and infection. An international team under the ... shown that these cells may actually make a significant ... disease. About 1.2 million people are thought to suffer ...
... Washington, DC Scientists at the Lombardi Comprehensive Cancer ... five-year $7.5 million grant to tease apart in the ... protein receptor in breast cells in cancer development and treatment. ... kind of breast cancer and how she will fare during ...
... <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-03/asu-etb031810.php,">Chinese . TEMPE, Ariz. ... ban the export of electronics waste would likely make ... of an article from the journal Environmental Science ... call into question conventional thinking that trade bans can ...
Cached Biology News:Dangerous custodians 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3E-waste trade ban won't end environmental threat 2
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
Kit for Detection of Mitochondrial Membrane Potential...
Biology Products: